Kilambi News
Sunday, November 22, 2026

Archive

Every story, newest first.

Saturday, October 31, 2026

Life Sciences

Vistagen cuts 31 percent of staff to fund fasedienol

Vistagen Therapeutics disclosed in an 8-K filed October 30 that it implemented a board approved workforce reduction of about 31 percent on October 26, expecting about 3.2 million dollars of annual savings against about 1.0 million dollars of severance costs.

Life Sciences

Tango pancreatic combination hits 82 percent response rate

Tango Therapeutics reported an 82 percent response rate in 22 evaluable patients for vopimetostat plus Revolution Medicines daraxonrasib in previously treated pancreatic cancer at ESMO, and plans a front line Phase 3 trial in the first half of 2027.

Life Sciences

Sanofi raises guidance as Dupixent sales jump 35 percent

Sanofi reported third quarter sales up 14.3 percent at constant exchange rates to 14.44 billion euros on October 30, with Dupixent sales up 34.8 percent to 5.7 billion euros, and raised full year guidance for the second time this year.

Life Sciences

Parse and Nomic build 100 million cell immune dataset

Parse Biosciences and Nomic Bio announced Cascade, a licensable dataset combining 100 million single cell RNA profiles with more than 11,000 proteomic secretome profiles across over 150,000 perturbation conditions, with GSK, Pfizer and Sanofi among the founding partners.

Life Sciences

Opentrons raises $40 million to scale AI lab robotics

Opentrons Labworks announced a 40 million dollar Series E led by Avego, with BroadOak Capital Partners participating, to scale its laboratory robotics, software and data infrastructure for AI driven experimentation.

Life Sciences

Moderna shares slide despite strong cancer vaccine data

Moderna shares fell by double digits during the ESMO congress even though detailed data for intismeran autogene, its personalised cancer vaccine with Merck, appeared to meet high expectations after a landmark melanoma trial win in August.

Life Sciences

Ivonescimab extends survival in biliary tract cancer trial

Akeso ivonescimab plus chemotherapy extended median overall survival to 14.9 months against 12.1 months for durvalumab plus chemotherapy in the Phase 3 HARMONi-GI1 trial in first line biliary tract cancer, a hazard ratio of 0.75, presented at ESMO.

Mining

Gold hits one year low as miners lose most ground

Spot gold fell as much as 3.2 percent to 3,891.67 dollars an ounce on Friday, its weakest level in a year, and silver broke below 50 dollars as investors sold metals to cover losses in sliding technology stocks.

Mining

Five workers die at Implats operations in September quarter

Impala Platinum reported five worker deaths at its South African operations in the quarter to September 30, four at Impala Rustenburg and one at Marula, against none across the group a year earlier.

Mining

American Tungsten completes Del Sol refinery acquisition in Nevada

American Tungsten and Antimony has completed its acquisition of Nexus Metals and the Del Sol hydrometallurgical refinery in Nevada for 2.6 million dollars in cash plus about 1.024 billion shares.